Trial Profile
The retrospective analysis- Percutaneous Hepatic Perfusion (Chemosaturation) with Melphalan in Patients with Intrahepatic Cholangiocarcinoma: European Multicentre Study on Safety, Short Term Effects and Survival
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Oct 2018
Price :
$35
*
At a glance
- Drugs Melphalan (Primary)
- Indications Cholangiocarcinoma
- Focus Adverse reactions; Therapeutic Use
- 11 Oct 2018 New trial record
- 04 Oct 2018 According to a Delcath Systems media release, Dr. Steffen Marquardt of Hannover Medical School is the lead author of this study.
- 04 Oct 2018 Results presented in the Delcath Systems media release.